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ABSTRACT
Objectives: There is limited evidence that giving Vitamin D supplementation had a beneficial effect on insulin resistance and dysfunction of 
the menstrual cycle in females with polycystic ovary syndrome (PCOS). Thus, the aim of the present study is to evaluate the effect of Vitamin D 
supplementation on insulin sensitivity and androgen level in Iraqi females with PCOS.
Methods: A randomized, blinded clinical trial design studied 60 Iraqi females with PCOS referring to the women’s counseling, outpatients at maternity 
and pediatrics teaching hospital in AL-Qadisiyah city, Iraq, and private clinic. Non-probabilistic sampling involved women aged from 18 to 45 years 
established on inclusion criteria. The patients’ basic data have been recorded. Then, we measured Vitamin D, testosterone level, and impaired glucose 
tolerance (IGT) test to all females. After the diagnosis of Vitamin D deficiency, Vitamin D was administering at 5000 units daily for 8 weeks. All data 
were remeasured after 2 months.
Result: A total of 60 patients with polycystic syndrome enrolled in the study, age range from 18 to 39 years, mean age 27.48±5.95 years. The metabolic 
parameter have been checked at the beginning of the study, which include Vitamin D level 16.1±5.6, impaired glucose test reading 8.8±0.7 and 
testosterone level 4.5±0.64.. After 2 months of supplementation, there were 83.7% of patients reach the normal level of Vitamin D and 16.3% still had 
a low level of Vitamin D (p≤0.002) between two groups. In regard to IGT test after 2 months of supplementation, there were 51.6% of patients still 
who had impaired test while 48.4% reach the normal reading (p≤0.001).
Conclusions: Women with PCOS have a statically significant low level of Vitamin D in mean, IGT test in the mean, and high level of testosterone, and 
there were inverse correlations between Vitamin D with IGT and testosterone.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common ovarian disorder 
associated with the disturbances of reproductive, hyperinsulinemia, and 
androgen excess in women [1]. Definition and diagnosis of PCOS are based on 
criteria including clinical evidence of hyperandrogenism, ovarian dysfunction 
such as oligoovulation, and the exclusion of other causes of hyperandrogenism 
such as adrenal hyperplasia, hyperprolactinemia, and thyroid disorders [2]. 
PCOS is associated with insulin resistance, hypertension, central lipidemia, 
and central venous dysfunction, all of which are risk factors for metabolic 
syndrome, type 2 diabetes, and coronary artery disease [3].
Metabolic disturbances are common in PCOS women: 30–40% have 
glucose tolerance disorder, 60–80% are resistant to insulin, and 10% have 
type 2 diabetes in their 30s or 40s. Evidence suggests the pivotal role of 
insulin resistance in PCOS pathogenicity [4]. Decrease level of Vitamin D is 
common in women with PCOS [5]. Vitamin D deficiency in PCOS women 
was associated with a reduced likelihood of these women becoming 
pregnant and delivering babies, regardless of body mass index (BMI), race, 
age, markers of metabolic functioning, or fertility treatment” [6]. Vitamin 
D has been associated with reducing androgen levels in women with 
PCOS. A review of six clinical trials with 183 women with PCOS revealed 




After having permission from the Ethics Committee of AL-Qadisiyah 
University of Medical Sciences, this study was conducted as a 
randomized, blinded clinical trial design from April 2018 to June 
2018, and we studied 60 Iraqi females with polycystic ovary syndrome 
referring to the women’s counseling, outpatients at maternity and 
pediatrics teaching hospital in AL-Qadisiyah city, Iraq. In our study, 
the aim of the project was explained to all females, and if they agreed, 
informed consent was obtained.
5. All women which included in this study have testosterone level 
between 3.5 and 5 nmol/L (normal level of testosterone in females 
between 0.5 and 3.5 nmol/L).
7. Screening for impaired glucose tolerance (IGT) test, and women with 
2 h plasma glucose level of 140–199 mg/dl (7.8–11.0 mmol/L) were 
involved in this study.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i12.29036
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should  encounter  at  least  two  things  of  these  criteria 
including:  Oligoovulation  or  anovulation,  hyperndrogenesis 
with  a  clinical  or  laboratory  diagnosis.  and,  Polycystic 
ovary  characterized  by  ultrasound  that  means  atleast  12 
follicles  per  ovary,  or  9–2  mm  in  size,  or  ovarian  enlargement 
more than 10 ml (obtained from the formula (0.5 - length - width
 - thickness) in ultrasound [8].
Inclusion criteria
The following criteria were included in the study:
1. Age of women ranges from 18 to 45 years.
2. Serum Vitamin D below 30 ng/ml.
3. Women should not being pregnant or lactating.
4. Rotterdam criteria for PCOS diagnosis have been use [2] so patient
 
6.  Drugs  which  affect  metabolic  parameters  such  
as  metformin,  Corticosteroid  3  months  before  
the  experiment ,  calcium  and  multivitamin  3  months  
before  the experiment did not be used.
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Sixty patients with polycystic syndrome enrolled in this study age 
ranging from 18 to 39 years, mean age 27.48±5.95 years, as shown 
in Table 1. In the beginning of the study, the level of Vitamin D was 
16.11±5.6 and, after 2 months, became 35.9±4.3 which is a significant 
difference (p=0.002) as shown in Table 2.
In regard to IGT test after 2 months of supplementation, there were 
51.6% of patients still who had impaired test while 48.4% reach the 
normal reading (p=0.001) (Table 3). On the other hand, 75% of patients 
reach the normal level of testosterone and 25% had abnormal level 
(p=0.001) (Table 4).
Table 5 shows inverse correlations between Vitamin D with IGT 
and testosterone, which mean an increase in Vitamin D level after 
supplementation leading to decrease in serum level of testosterone (p=0.02) 
and also decrease in the reading of impaired tolerance test (p=0.04).
DISCUSSION
Our result indicated women with PCOS have a significant low level of 
Vitamin D in mean 16.11±5.6, IGT test in mean 8.8±0.8, and high level of 
testosterone in mean 4.5±0.6 [10,11]. These indicate that low Vitamin D 
levels are associated with insulin resistance in women with PCOS [12]. 
Our data suggest a relationship of Vitamin D and BMI in PCOS women, 
which is in agreement with many studies [8,13,14]. Other studies 
suggest that low Vitamin D levels are related to impaired glucose 
clearance, insulin secretion, and insulin resistance [15,16].
The IGT level at baseline was 8.8±0.9, and after treatment, 48.4% 
became normal reading (6.4±0.8); t-test showed a significant difference 
between the level of IGT before and after treatment (p<0.05).
On the other hand, the level of testosterone was 4.5±0.6 before 
treatment, while 75% after treatment decreases to normal level 
(2.2±0.4) (p<0.05). A significant fall in serum testosterone was 
observed in 2 months in comparison with the baseline in the same 
group. A similar result has also been described in a study by Pal et al. [9]. 
Several factors may be able to explain the conflicting results, including 
the different characteristics of the research subjects, the length of study, 
and the various Vitamin D forms used for supplementation [17-19].
CONCLUSION
Women with PCOS have statistically significant low level of Vitamin 
D in mean, IGT test in mean, and high level of testosterone in mean. 
After Vitamin D supplementation for 2 months, 42 of 54 PCOS women 
previously affected by menstrual disturbances reported improvement 
of menstrual frequency. Also  there was marked reduction in the level of 
IGT after treatment with Vitamin D have been reported. Furthermore, 
there is an improvement in the symptom of hyperandrogenism.
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